CDK6: an attractive therapeutic target for T-ALL/LBL.
Wei LiJamie Katy HuMiaofen G HuPublished in: Expert opinion on therapeutic targets (2023)
. Numerous clinical trials of CDK4/6 inhibitors are ongoing in T-ALL. Specific CDK6 inhibitors alone or novel combination regimens may hopefully delay the progression, or even reverse the symptoms of T-ALL, leading to disease eradication and cure.